Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia in Remission; Aggressive Non-Hodgkin Lymphoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Diffuse Large B-Cell Lymphoma; Hematopoietic and Lymphoid Cell Neoplasm; Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm; Plasma Cell Myeloma; Refractory Chronic Lymphocytic Leukemia; Refractory Hodgkin Lymphoma; Waldenstrom MacroglobulinemiaInterventions: Procedure: Total-Body Irradiation; Drug: Fludarabine Phosphate; Drug: Mycophenolate Mofetil; Drug: Cyclosporine; Procedure: Peripheral Blood Stem Cell TransplantationSponsors: Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)Active, not recruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cardiology | Chronic Leukemia | Chronic Myeloid Leukaemia | Heart | Heart Transplant | Hematology | Leukemia | Lung Transplant | Lymphoma | Myeloma | Research | Restasis | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants